• Tempus AI agreed to acquire Personalis for USD 16.25 per share, valuing the deal at USD 1.5 billion net of Tempus’ existing stake.
• Consideration is all stock with a floating exchange ratio, capped at 0.3356 Tempus shares per Personalis share.
• Tempus can elect to pay up to 50% of consideration in cash, funded by cash on hand and existing credit facilities.
• Closing is expected in late 2026 or early 2027, subject to shareholder and regulatory approvals.
• Personalis reported preliminary Q2 revenue of USD 22.4 million, with 10,384 clinical tests delivered, up 33% quarter over quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260720359246) on July 20, 2026, and is solely responsible for the information contained therein.